

For immediate release

30 December 2024



ALLIANCE PHARMA PLC
("Alliance" or the "Company")

Block Listing Six Monthly Return

Name of applicant:		ALLIANCE PHARMA PLC		
Names of schemes:		a) The Alliance Pharma plc Share Option Plan 2006 b) The Alliance Pharma plc Company Share Option Plan 2015 c) The Alliance Pharma plc Long-Term Incentive Plan 2019		
Period of return:	From:	28 June 2024	To:	28 December 2024
Number of securities originally admitted at date of admission:		25,000,000 ordinary shares of 1p each 28 June 2017		
Balance of unallotted securities under schemes from previous return:		a) 2,443,011 b) 9,572,622 c) 1,028,457		
<u>Plus:</u> The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for):		a) Nil b) Nil c) Nil		
<u>Less:</u> Number of securities issued/allotted under schemes during period:		a) Nil b) Nil c) Nil		
<u>Equals:</u> Balance under schemes not yet issued/allotted at end of period:		a) 2,443,011 b) 9,572,622 c) 1,028,457		

Name of contact:	Chris Chrysanthou, Company Secretary
Telephone number of contact:	Tel. +44 (0)1249 705166

For further information:

Alliance Pharma plc
Head of Investor Relations: Cora McCallum
ir@allianceph.com

+ 44 (0)1249 466966
+ 44 (0)1249 705168

Buchanan
Mark Court / Sophie Wills
alliancepharma@buchanan.uk.com

+ 44 (0)20 7466 5000

Deutsche Numis (Nominated Adviser and Joint Broker)
Nominated Adviser: Freddie Barnfield / Duncan Monteith / Sher Shah

+ 44 (0)20 7260 1000

Investec Bank plc (Joint Broker)
Patrick Robb / Maria Gomez de Olea

+ 44 (0)20 7597 5970

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BLRURABRSWUOAA